HCPLive

Calorie-Restricted Weight Loss Restores Ghrelin Sensitivity

 
MONDAY, Jan. 21 (HealthDay News) -- In a mouse model, calorie-restricted weight loss reverses the high-fat diet-induced ghrelin resistance that may contribute to rebound weight gain, according to research published online Jan. 10 in Endocrinology.

Noting that high-fat diet feeding causes ghrelin resistance in neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons, Dana I. Briggs, Ph.D., of Monash University in Clayton, Australia, and colleagues used a diet-induced obese (DIO) mouse model to study the role of ghrelin resistance in diet-induced weight loss and rebound weight gain. DIO mice were allocated to receive chow ad libitum or chow diet with 40 percent calorie restriction until they reached the weight of age-matched lean controls.

The researchers found that body weight, glucose tolerance, and plasma insulin all normalized with both dietary interventions. Calorie restriction-induced weight loss correlated with increased plasma ghrelin, restoration of ghrelin sensitivity, and increases in total NPY/AgRP mRNA expression.

"We show that calorie-restricted weight loss after diet-induced obesity restores the ability of ghrelin to induce food intake, indicating a reversal of diet-induced obesity ghrelin resistance with diet-induced weight loss," the authors write. "We suggest long-term diet-induced obesity changes the body weight setpoint, and as the body interprets calorie-restricted weight loss as negative energy balance, ghrelin fights to defend this higher body weight. This represents a novel target to restrict rebound weight gain in humans."
 

Abstract
Full Text (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

Besides being the most common cause of chronic liver disease in industrialized nations, non-alcoholic fatty liver disease has serious hepatic consequences. It is expected to be the most frequent indication for liver transplantation by 2030.
Here, the panelists offer their final take-home points on optimizing outcomes in HIV treatment for viewers.
This segment focuses first on the SPRING-2 trial in treatment-naïve patients, followed by a discussion of the SAILING trial, which studied a treatment-resistant population. SPRING-2 was one of the key phase 3 studies in a treatment-naïve population.
The herpes virus has found its sole positive use: to combat melanoma, the deadliest of skin cancers.
$vAR$